The adolescent and young adult with cancer: State of the art - Acute leukemias

Current Oncology Reports

Volumn 15, Issue 4, 2013, Pages 317-324

  Gramatges, M Monica ^a   Rabin, Karen R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Adherence; Adolescent; Hyperglycemia; Obesity; Osteonecrosis; Pancreatitis; Thromboembolism; Treatment related toxicity; Young adult

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DRUG METABOLIZING ENZYME; GLUCOCORTICOID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT HEALTH; AGE DISTRIBUTION; AGE SPECIFIC CARE; ARTICLE; AVASCULAR NECROSIS; BACTEREMIA; BCR ABL1 GENE; BODY MASS; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RESISTANCE; CANCER SURVIVAL; CAUCASIAN; CELLULITIS; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CRLF2 GENE; DIPLOIDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FAMILY HISTORY; FLT3 ITD GENE; FUNGEMIA; FUSION GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IKZF1 GENE; INDUCTION CHEMOTHERAPY; INFECTION; INFECTION RISK; JAK GENE; KIDNEY FUNCTION; LIVER FUNCTION; LONG TERM CARE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MLL GENE; MONOTHERAPY; OBESITY; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PEER GROUP; POPULATION RESEARCH; PSYCHOSOCIAL CARE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SOCIAL INTERACTION; STEROID THERAPY; SURVIVAL PREDICTION; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; OBESITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; STEROIDS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84880794502     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0325-5     Document Type: Article

References (71)

1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018.
2. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119(1):34-43. doi: 10.1182/blood-2011-04-347872.
3. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013. doi: 10.1016/S0140-6736(12)62187-4.
4. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2004:118-45. doi: 10.1182/asheducation-2004.1.118.
5. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. (Pubitemid 41039178)
6. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004;104(13):4173-80. doi: 10.1182/blood-2003-11-3944. (Pubitemid 39620171)
7. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43. doi: 10.1016/S0140-6736(08)60457-2. (Pubitemid 351389536)
8. Chiaretti S, Messina M, Tavolaro S, Foa R. Myeloid/T-cell acute lymphoblastic leukemia in children and adults. Pediatr Rep. 2011;3 Suppl 2:e3. doi: 10.4081/pr.2011.s2.e3.
9. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-205. doi: 10.1182/blood-2012-03-362608.
10. Radhi M, Meshinchi S, Gamis A. Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep. 2010;5(4):200-6. doi: 10.1007/s11899-010-0060-z.
11. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372-9. doi: 10.1182/blood-2009-09-241075.
12. Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14(8):2370-6. (Pubitemid 26264890)
13. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809-17. doi: 10.1182/blood-2002-08-2454. (Pubitemid 36857851)
14. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-45. doi: 10.1111/j.1365-2141. 2005.05509.x. (Pubitemid 40904523)
15. Schrappe M, Zimmerman M, Moricke A, Mann G, Valsecchi M, Bartram C. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000). Blood. 2008;112:7.
16. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5(2):202-7. (Pubitemid 17021600)
17. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200-7. (Pubitemid 8160340)
18. Mattano Jr LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18(18):3262-72.
19. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19(12):3066-72. (Pubitemid 32565445)
20. Mattano L, Nachman J, Devidas M, Winick N, Raetz E, Carroll W. Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group (COG). Blood. 2008;112:898.
21. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-0. J Clin Oncol. 2013;31(9):1202-10. doi: 10.1200/JCO.2012.43.2070.
22. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25(8):1232-8. doi: 10.1038/leu.2011.84.
23. •• Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009;27(31):5189-94. doi: 10.1200/JCO.2008.20.8959. Results of a randomized phase III trial of 262 young adults with ALL demonstrate the benefit of early post-induction intensification therapy. The authors argue that the excellent outcomes on this trial support the use of chemotherapy rather than allogeneic stem cell transplant as front-line therapy for young adults with ALL.
24. Arico M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R, et al. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica. 2003;88(7):747-53. (Pubitemid 36890108)
25. Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29(4):386-91. doi: 10.1200/JCO.2010.32.0325.
26. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22(19):3930-6. doi: 10.1200/JCO.2004.11.020. (Pubitemid 41079875)
27. Gong LL, Fang LH, Wang HY, Peng JH, Si K, Zhu J, et al. Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis. Steroids. 2013;78(4):401-8. doi: 10.1016/j.steroids.2013.01.004.
28. Niinimaki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Paakko EL, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 2007;25(12):1498-504. doi: 10.1200/JCO.2006.06.2539. (Pubitemid 46733076)
29. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340-7. doi: 10.1182/blood-2010-10-311969. quiz 556.
30. Bond J, Adams S, Richards S, Vora A, Mitchell C, Goulden N. Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;118(9):2632-3. doi: 10.1182/blood-2011-05-355206.
31. French D, Hamilton LH, Mattano Jr LA, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(9):4496-9. doi: 10.1182/blood-2007-11-123885.
32. Mattano Jr LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906-15. doi: 10.1016/S1470-2045(12)70274-7.
33. Leblicq C, Laverdiere C, Decarie JC, Delisle JF, Isler MH, Moghrabi A, et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatric blood & cancer. 2013;60(5):741-7. doi: 10.1002/pbc.24313.
34. Winick N, Salzer W, Devidas M. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group study AALL0232. Programs/Proceedings American Society of Clinical Oncology. 2011
35. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatric blood & cancer. 2009;53(2):162-7. doi: 10.1002/pbc.22076.
36. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatric blood & cancer. 2007;49(5):634-9. doi: 10.1002/pbc.21037. (Pubitemid 350194426)
37. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-8. (Pubitemid 32183741)
38. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129(6):803-10. doi: 10.1111/j.1365-2141.2005.05528.x. (Pubitemid 40904532)
39. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, et al. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia. 2009;23(2):245-50. doi: 10.1038/leu.2008.289.
40. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 1981;99(1):46-50. (Pubitemid 11046416)
41. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2008;51(3):387-92. doi: 10.1002/pbc.21624.
42. Roberson JR, Raju S, Shelso J, Pui CH, Howard SC. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(6):1207-12. doi: 10.1002/pbc.21505. (Pubitemid 351555545)
43. • Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25(15):2063-9. doi: 10.1200/JCO.2006.07.7792. Retrospective analysis of children with newly diagnosed ALL demonstrates an increased risk of relapse associated with obesity, with greatest risk in patients over 10 years of age. (Pubitemid 46972792)
44. Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006;108(13):3997-4002. doi: 10.1182/blood-2006-05-024414. (Pubitemid 44913268)
45. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA: J Am Med Assoc. 2005;293(2):203-11. doi: 10.1001/jama.293.2.203. (Pubitemid 40095871)
46. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45(7):881-91. doi: 10.1002/pbc.20451. (Pubitemid 41552155)
47. Zuccaro P, Guandalini S, Pacifici R, Pichini S, Di Martino L, Guiducci M, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit. 1991;13(1):37-41.
48. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol. 1998;37(3):277-84. (Pubitemid 28307853)
49. Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D'Incalci M, Masera G, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24(3):154-9.
50. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45(12):1227-38. (Pubitemid 44904825)
51. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67. doi: 10.1056/NEJMra035092. (Pubitemid 37122329)
52. • Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol. 2010;28(32):4790-9. doi: 10.1200/JCO.2010.28.3473. Comprehensive review of developmental physiology and behavioral characteristics that affect pharmacology of anti-cancer agents in the AYA population.
53. Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110(4):813-8.
54. Maung ZT, Reid MM, Matheson E, Taylor PR, Proctor SJ, Hall AG. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br J Haematol. 1995;91(1):93-100.
55. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst. 2008;100(18):1301-9. doi: 10.1093/jnci/djn276.
56. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25(7):813-9. doi: 10.1200/JCO.2006.08.6397. (Pubitemid 350002881)
57. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernandez-Abellan P, del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265.
58. Truong TH, Beyene J, Hitzler J, Abla O, Maloney AM, Weitzman S, et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer. 2007;110(8):1832-9. doi: 10.1002/cncr.22990. (Pubitemid 47557309)
59. Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677-84. doi: 10.1002/cncr.20532. (Pubitemid 39318917)
60. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999;106(2):436-44. (Pubitemid 29450670)
61. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):2705-13. (Pubitemid 32441376)
62. •• Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495-502. doi: 10.1002/cncr.21892. Retrospective review of 424 children with AML treated during two treatment eras (1983-1989 and 1990-2002) demonstrates an increased risk of adverse events associated with older age in the recent era, and an increased risk of death associated with increasing age in both treatment eras. (Pubitemid 43787676)
63. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384-93. doi: 10.1200/JCO.2004.01.191. (Pubitemid 41185159)
64. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110(10):3532-9. doi: 10.1182/blood-2007-05-091942. (Pubitemid 350159617)
65. Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115(5):1100-8. doi: 10.1002/cncr.24107.
66. Gramatges MM, Winter SS. Recommendations for broader coverage antifungal prophylaxis in childhood acute myeloid leukemia: ASH evidence-based review 2011. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011;2011:374-6. doi:10.1182/asheducation-2011.1.374
67. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93. doi: 10.1093/cid/cir073.
68. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011;8(7):417-24. doi: 10.1038/nrclinonc.2011.77.
69. Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood. 2011;117(22):5803-15. doi: 10.1182/blood-2010-12-283093.
70. Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012;30(17):2094-101. doi: 10.1200/JCO.2011.38.9924.
71. • Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800-9. doi: 10.1200/JCO.2009.22.2802. Review of issues and clinical challenges of nonadherence in AYA patients with cancer. While evidence-based research is lacking, this review provides a valuable outline of strategies for assessment and management of nonadherence, and areas where future research is needed.